Dateline City:
KENILWORTH, N.J.
Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028
Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that updated findings from the phase 1b KEYNOTE-028
study investigating the use of KEYTRUDA (pembrolizumab), the
companys anti-PD-1 therapy, in previously treated patients with
advanced small cell lung cancer (SCLC) and malignant pleural
mesothelioma, showed clinical activity and durable responses in some
patients.
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more